Miglustat G.L. (Miglustat)

Miglustat inhibits the enzyme glucosylceramide synthase, which catalyzes the first step in glycosphingolipid synthesis. By blocking this enzyme, the drug reduces the production of glucosylceramide and related lipids, decreasing their buildup in cells affected by Gaucher disease type 1 and Niemann‑Pick disease type C.

The dosage of Miglustat G.L. is individualized by the prescribing clinician based on the patient’s age, weight, disease severity, and renal function. Only a qualified healthcare professional can determine the appropriate dose and schedule.

The safety of miglustat in pregnancy and lactation has not been established, and the product carries an unknown pregnancy category. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Miglustat is a substrate reduction therapy, whereas enzyme replacement therapies (ERT) provide the missing enzyme directly. Miglustat is taken orally and can cross the blood‑brain barrier, offering potential benefit for neurological involvement, while ERTs are administered intravenously and do not address central nervous system symptoms.

Miglustat G.L. should be stored at temperatures below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it in a dry place away from direct sunlight to maintain stability.

Miglustat G.L. is taken orally, usually with a glass of water. The prescribing physician will give specific instructions regarding timing relative to meals and any necessary dose adjustments based on tolerability and clinical response.

The most serious adverse events include pancreatitis, severe hypersensitivity reactions, significant liver enzyme elevations, and neuropsychiatric effects such as depression or seizures. Patients should be monitored regularly, and any concerning symptoms should prompt immediate medical evaluation.

Miglustat G.L. is contraindicated in individuals with known hypersensitivity to miglustat or any of its excipients. Caution is advised for patients with pre‑existing liver disease, uncontrolled diabetes, or a history of severe psychiatric disorders, and it should be avoided in those for whom oral administration is not feasible.